What Sooma does

Sooma Oy, headquartered in Helsinki, Finland and founded in 2013, develops and manufactures Sooma tDCS™, a non-invasive transcranial direct current stimulation device that delivers mild electrical currents through scalp electrodes to treat major depressive disorder and chronic pain conditions including fibromyalgia and neuropathic pain. The core product ecosystem centers on the portable stimulation device (with predefined electrode positions in a head cap), the proprietary ComfoTrode reusable electrodes and disposable ComfoPad gel pads, the Sooma Portal clinician platform for remote protocol customization and adherence monitoring, and a patient-facing mobile app that guides treatment sessions. All hardware is manufactured in Finland under ISO 13485 quality management, and the system carries EU MDR certification (first tDCS system to do so), CE marking, Health Canada, MDA, HSA, COFEPRIS, and FDA Breakthrough Device Designation with an active Investigational Device Exemption for U.S. clinical trials.

The company monetizes through a hybrid hardware-plus-subscription model: clinics and hospitals purchase devices for supervised use, while patients in Finland and Germany can now order directly via the Sooma webshop at €599 one-time or €129/month for a 6-month treatment course (80 sessions), with continuation therapy at €279 one-time or €49/month. Go-to-market combines enterprise field sales to hospitals and psychiatric clinics (300+ globally, including NHS England, Karolinska Institutet, TUM/LMU, and Turku University Hospital), a direct-to-patient e-commerce channel launched in December 2025, and a distributor network spanning 35+ countries. Cumulative scale includes 30,000+ patients treated and 500,000+ sessions administered, with clinical evidence anchored by a 410-patient peer-reviewed study (Lõokene et al., 2022) reporting a 55% response rate within three weeks. Sooma is venture-backed with a €5M seed round in March 2024 led by Voima Ventures, and in July 2025 transitioned founder Tuomas Neuvonen from CEO to CTO while appointing Andreas Hartlep as CEO to accelerate international and U.S. market entry.

Name

Sooma

Legal name

Sooma Oy

Website

https://soomamedical.com

Company type

Private

Founded year

2013

Operating status

Operating

Headcount range

1–10 employees

Short description

Sooma Oy is a Finnish medical device company that develops and markets Sooma tDCS™, a non-invasive transcranial direct current stimulation system for treating depression and chronic pain, sold to hospitals, clinics, and directly to patients across 35+ countries.

Ownership category

akta.pro rank

Product category

Neuromodulation Medical Devices

NAICS

Computer Systems Design and Related Services (54151)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Condition-specific Digital Therapeutics (DTx) (HLACANAA)

akta.pro secondary industry

Therapeutic Companion Apps (Drug-Device-Digital Combination) (HLACANAH)

Keywords

• Non-invasive brain stimulation
• Transcranial direct current stimulation
• Depression treatment devices
• Chronic pain neuromodulation
• TDCS medical devices

Headquarters

HQ city

Helsinki

HQ country

Finland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Supply Chain, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. tDCS Device Sales: Sale of Sooma tDCS stimulation devices with bundled treatment protocols. Devices sold as one-time purchases or as part of treatment packages. Device remains patient-owned but locks after treatment period completes.
2. Treatment Subscription: Monthly subscription payments for 6-month treatment courses including device access, 80 treatments, and app support. Continuation therapy subscriptions for ongoing treatment cycles.
3. Direct-to-Patient Sales: Direct consumer sales launched in 2025, allowing patients to order treatment directly without physician referral, expanding revenue beyond clinical channel.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

Core offering

Sooma develops, manufactures, and sells the Sooma tDCS system—a portable, non-invasive transcranial direct current stimulation medical device for treating major depressive disorder and chronic pain conditions. The offering includes the tDCS device with patent-protected ComfoTrode electrodes and ComfoPad gel pads, the Sooma Portal clinician remote-monitoring platform, the Sooma Mobile App for patient treatment guidance, and treatment protocols sold as 6-month courses or continuation subscriptions to healthcare providers and (in Finland/Germany) directly to patients.

Product overview

Sooma offers a unified product ecosystem centered on the Sooma tDCS™ device—a non-invasive transcranial direct current stimulation system for depression and chronic pain treatment. The core device is complemented by the Sooma Portal for clinician remote monitoring and protocol management, a patient-facing mobile app for guided treatment sessions, and consumable accessories (ComfoTrode electrodes and ComfoPad gel pads). Treatment protocols are delivered via a head cap with predefined electrode positions. The Sooma Clinic service provides in-person treatment in Finland through healthcare facilities. All products are designed and manufactured in Finland under ISO 13485 quality standards.

Differentiator

Problem solved

Functional benefit

Products and services

• Sooma tDCS Non-invasive transcranial direct current stimulation device for treating major depressive disorder and chronic pain. Delivers mild electrical current to brain regions responsible for depressive behavior and pain processes through a cap with predefined electrode positions. Available for clinical and at-home use.
• Sooma Clinic Healthcare service in Finland offering Sooma tDCS treatment with physician referral, delivered through appointments and remote connections supervised by medical professionals.

Quantifiable outcome

• 55% of patients experienced at least 50% symptom reduction within 3 weeks in peer-reviewed study of 410 patients
• +6 more outcomes

Named customers7 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Neuroelectrics: Barcelona-based developer of Starstim and other HD-tDCS/tACS systems used in clinical and research settings for depression, epilepsy, and other brain disorders. Directly competes with Sooma in the same transcranial direct current stimulation modality with overlapping customer base in hospitals and research institutions.
• Soterix Medical: US-based developer of tDCS, tACS, and tRNS systems including the 1×1, 4×1, and High-Definition devices used widely in clinical trials and clinical neurology. Closest direct technology competitor to Sooma in tDCS hardware and accessories.
• Ybrain: South Korean company that developed a wearable tDCS headband for depression and cognitive disorders with similar clinical evidence claims. Direct competitor in the same tDCS-for-MDD category with comparable physician-channel distribution.
• Flow Neuroscience: Sweden-based company offering a home-use tDCS headset combined with behavioral therapy for depression, sold via clinician referral and direct channels in Europe. Highly comparable to Sooma's tDCS-for-MDD positioning, at-home model, and European footprint.

Broad incumbents

• Brainsway: Israel/US-listed provider of Deep TMS systems (H-coil) FDA-cleared for MDD, OCD, and smoking cessation. Competes with Sooma for the same psychiatrist budgets and treatment-resistant depression patient population, but using a different (magnetic) modality.
• Neuronetics: US-listed company behind the NeuroStar TMS system, the leading FDA-cleared TMS device for MDD. Competes with Sooma for treatment-resistant depression patients and clinic capex, with broader commercial reach in US psychiatry.
• MagVenture: Danish manufacturer of TMS systems (MagPro) used in clinical practice and research for depression and other psychiatric conditions. Adjacent competitor serving the same psychiatrist customer base via a different neuromodulation modality.
• Magstim: UK-based manufacturer of TMS stimulators and coils widely used in research and clinical depression treatment. Competes for clinic budgets and clinician attention in the same neuromodulation category, although with a magnetic rather than electrical modality.

Emerging players

• Big Health: US-based digital therapeutics company offering Sleepio (insomnia) and Daylight (anxiety), evidence-based CBT-based software products that compete for the same treatment-resistant depression and anxiety payer/pharmacy budgets but via a software-only modality.
• Akili Interactive: US digital therapeutics company with FDA-cleared EndeavorRx (ADHD) and broader cognitive/mental health software pipeline. Competes with Sooma for digital therapeutic reimbursement and physician mindshare in mental health but via a different, purely software modality.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/sooma-oy
• Xx.com/soomamedical
• Facebookfacebook.com/soomamedical

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds7 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sooma